Table 1.
Patient baseline characteristics
| Total (N = 400) | |
|---|---|
| Age | 58 (52, 63) |
| Gender (%) | |
| Men | 49 |
| Women | 51 |
| Race (%) | |
| White | 58 |
| Black | 36 |
| Other | 6 |
| Hypertension (%) | 73 |
| Systolic BP (mmHg) | 128 (118, 136) |
| Diastolic BP (mmHg) | 75 (70, 80) |
| Waist Circumference (in) | 42 (38, 46) |
| BMI (kg/m2) | 31.7 (28.0, 36.2) |
| Glucose (mg/dL) | 112 (95, 139) |
| Hemoglobin A1c (%) | 6.7 (6.2, 7.5) |
| Serum Creatinine (mg/dL) | 0.88 (0.70, 1.0) |
| BUN (mg/dL) | 16 (13, 19) |
| eGFR (CKD-EPI) | 91.7 (80.0, 102.1) |
| Urinary ACR (mg/g) | 5.3 (3, 13.5) |
| Anti-Hypertensive Medications (%) | |
| ACE Inhibitor or ARB | 61 |
| Diuretic | 32 |
| CCB | 16 |
| Beta Blocker | 12 |
| Lipid-Lowering Medications (%) | |
| Statin | 52 |
| Fibrate | 7 |
| Niacin | 4 |
| Lp(a) (mg/dL) | 25 (9, 57) |
| ApoC-III (mg/dL)* | 11.4 (8.7, 15.6) |
| Triglycerides (mg/dL) | 105 (79, 156) |
| LDL-C (mg/dL) | 99 (79, 119) |
| Apolipoprotein B (mg/dL) | 80 (69, 94) |
Characteristics of cohort at baseline visit. All data reported as median (interquartile range) unless otherwise specified
BP blood pressure, BMI body mass index, BUN blood urea nitrogen, eGFR estimated glomerular filtration rate, ACR albumin to creatinine ratio, ARB angiotensin receptor blocker, CCB calcium channel blocker, Lp(a) lipoprotein(a), ApoC-III apolipoprotein C-III, LDL-C low density lipoprotein cholesterol
*N = 336